NEW YORK (GenomeWeb News) – Saladax Biomedical today said that it will offer its My5-FU assay as part of its MyCare service offering later this year after regaining marketing rights to the test from Myriad Genetics.

The Bethlehem, Pa.-based firm said that it would begin offering the assay, which is used to help guide optimized dosing of infusional 5-fluorouracil to patients, later this year when its CLIA lab commences operations in June. 5-FU is used to treat several types of cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.